Amplified in breast cancer 1 (AIB1) gene, has been reported to be associated with biological malignancy in several cancers. However, the molecular status of the AIB1 gene in cervical cancer and the clinicopathological/prognostic significance of AIB1 expression in chemoradiotherapy (CRT) sensitivity have not been determined. In our present study, we found that the high expression of AIB1 was frequent detected in specimens of cervical cancer patients, and this was significantly correlated with CRT response (P = 0.014), clinical stage (P = 0.003), T status (P = 0.027), N status (P = 0.021), M status (P = 0.015) and progression-free survival (P < 0.001). Moreover, the clonogenic survival fraction and cell apoptosis experiments showed that knockdown of AIB1 substantially increased cervical cancer cells sensitivity to ionizing radiation (IR) or cisplatin/5-fluorouracil. Collectively, our results demonstrated that the high expression of AIB1 in cervical cancer cells contributes to the resistance to CRT, which provides the evidence that AIB1 may be a promising predictor of aggressive cervical cancer patients with poor response to CRT.

Our findings provide evidence that MGMT promoter methylation could play an important role in gastric carcinogenesis and may serve as an important biomarker for gastric cancer progression.

Background: The diagnosis and treatment of diabetes depends on reasonable chronic disease management.Compared with urban areas, county areas are high-risk areas for chronic disease patients, due to the low awareness of chronic disease, poor treatment compliance with chronic disease, low drug persistence, and low cure rate. Therefore, more attention should be paid to chronic disease management in county areas. Methods: This retrospective, observational study was conducted at the Yun county medical community, Yun county, Yunan province. Data were collected from the medical records of diabetic patients from July 2017 to Aug 2020. The primary outcome variable was the proportion of patients with diabetic complications in county areas. The secondary outcome variables were demographics and clinical characteristics of diabetic patients in county areas, achievement of the HbA 1c target, and clinical inertia of diabetic patients in county areas. Comparisons of the simple diabetes group and the diabetic kidney disease (DKD) group in terms of demographics, clinical characteristics, treatment patterns, and health resource consumption were also conducted. A series of appropriate statistical tests were applied to the study population to examine the various outcomes.Results: A total of 9,721 type 2 diabetic patients were included for the study analysis. Diabetic retinopathy (11.83%), cerebrovascular disease (10.31%), and DKD (9.29%) were the 3 most common complications in overall admissions. Among the 1,347 patients with HbA1c test results, 536 (39.8%) patients achieved the HbA 1c target, while 566 (87.62%) of the 661 patients who did not achieve the HbA 1c target had clinical inertia during the next 6 months. Compared with simple diabetes patients, patients with DKD had a higher age, wider coverage of medical insurance, and longer duration of diabetes, and were more likely to be complicated with hyperuricemia, dyslipidemia, and hypertension. Regular insulin, metformin, alphaglucosidase inhibitor, and sulfonylurea were the most widely used antidiabetic drugs in patients with DKD.The health resources consumption also significantly increased. Conclusions:The proportion of complications in diabetic patients is high in county areas, and blood glucose control is still insufficient. Chronic complications are the key reasons for the decrease in quality of life and high medical costs.